Leveraging patient samples from those enrolled in the WOO-M trial (NCT04005690), which aims to study biological activity of metastatic PDAC lesions to the liver in response to targeted therapies, metastatic tumor tissue, and peripheral blood specimens, were collected at baseline and after 10 days of treatment with systemic targeted therapy with either a PLK-1 inhibitor (n = 2) or MEK inhibitor (n = 2), per the trial protocol. This evidence concerns the gene PLK1 and neoplasm.